Celgene (CELG): Relevance Fails, PT Drops To $147 - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Celgene (CELG) PT Lowered to $130 at Stifel; 'Revlimid Plus Ritxuan did not Achieve Superiority with Co-Primary Endpoints'
December 22, 2017 8:18 AM ESTStifel lowered its price target on Celgene (NASDAQ: CELG) to $130.00 (from $149.00) while maintaining a Buy rating, following the company's announcement regarding an update of Phase 3 trial Revlimid (Revevance).
Analyst Thomas Shrader notes a cautious outlook on the shares, commenting "that Phase III trial... More
